Search
Eptinezumab
go.drugbank.com/drugs/DB14040ApprovedInvestigational[F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]
Products: VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML, Vyepti® 100 mg/mL concentrate for solution for infusionLuspatercept
go.drugbank.com/drugs/DB12281ApprovedInvestigational[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … [A187835] Luspatercept's novel mechanism of action, then, is uniquely suited for the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and other myelodysplastic
Products: Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injectionInfliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalThey are approved for all eligible indications of the reference product. Inflectra, a first biosimilar drug product, was approved in 2016. … It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate
Categories: Biologics for Rheumatoid Arthritis Treatment, Tumor Necrosis Factor Receptor Blocking ActivityProducts: POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/VIAL, REMICADE POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100 mg/vialTriptorelin
go.drugbank.com/drugs/DB06825ApprovedInvestigationalVet approvedTriptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous ad...
Categories: Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor AgonistsProducts: POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial, Pamorelin Powder for Suspension for Injection 3.75 mgMitomycin
go.drugbank.com/drugs/DB00305ApprovedInvestigational[A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper
Products: MITONCO 10mg powder for solution for injection/infusion or intravesical, Mitomycin for InjectionUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalIn October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients.
Categories: Biologics for psoriasis treatmentProducts: STELARA CONCENTRATE FOR SOLUTION FOR INFUSION 130MG/26ML, STELARA 130mg/26mL Concentrate for Solution for InfusionAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment … [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023.
Products: Zaltrap 25mg/ml Concentrate for Solution for Infusion, ZALTRAP CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/MLSarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling
Categories: Biologics for Rheumatoid Arthritis Treatment, Interleukin-6 Receptor AntagonistProducts: KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG, KEVZARA Solution for Injection in Pre-filled Pen 150mgSodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigational[L2933] The treatment effect was maintained for up to 12 months.[L2933] … Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that
Categories: Drugs for Treatment of Hyperkalemia and HyperphosphatemiaProducts: LOKELMA POWDER FOR ORAL SUSPENSION 5G, LOKELMA POWDER FOR ORAL SUSPENSION 10GRamucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalVEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. … Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing
Categories: Vascular Endothelial Growth Factor Receptor 2 Antagonist, VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsProducts: CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML, CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML